Loading…
Cabaletta Bio, Inc. is projected to rise to $5.16 by 2027, a +35% move from its current price of $3.83. CABA is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $3.66 | $3.83 | $4.01 | 0.00% |
| May 30 | $3.59 | $3.83 | $4.09 | 0.00% |
| May 31 | $3.54 | $3.83 | $4.15 | 0.00% |
| Jun 1 | $3.50 | $3.83 | $4.20 | 0.00% |
| Jun 2 | $3.46 | $3.83 | $4.24 | 0.00% |
| Jun 3 | $3.42 | $3.83 | $4.28 | 0.00% |
| Jun 4 | $3.39 | $3.83 | $4.32 | 0.00% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.39 | $3.83 | $4.32 | 0.00% |
| Week 2 | $3.23 | $3.83 | $4.54 | 0.00% |
| Week 3 | $3.11 | $3.83 | $4.72 | +0.01% |
| Week 4 | $3.01 | $3.83 | $4.88 | +0.01% |
| Week 5 | $2.92 | $3.83 | $5.02 | +0.01% |
| Week 6 | $2.85 | $3.83 | $5.15 | +0.01% |
| Week 7 | $2.78 | $3.83 | $5.27 | +0.01% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Cabaletta Bio, Inc. is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. The company’s lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, systemic lupus erythematosus, relapsing and progressive multiple sclerosis, mucocutaneous and mucosal pemphigus vulgaris (PV), systemic sclerosis, and generalized myasthenia gravis.
It also develops DSG3-CAART, a CAAR T cell therapy that is in Phase 1 clinical trial for the treatment of mucosal PV; and MuSK-CAART, an investigational cell therapy in Phase 1 trial for treating patients with anti-muscle-specific kinase (MuSK) antibody positive myasthenia gravis. It has collaborations with the University of Pennsylvania and the Children’s Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; Autolus Holdings (UK) Limited; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc.
and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
Cabaletta Bio, Inc. (CABA) is a clinical-stage biotechnology company focused on engineered T cell therapies for autoimmune diseases. The current price is $3.65 per share, and the market cap is $595.15M, with a rank of 2907.
The stock trades within a spectrum of potential future prices reflected in a year-by-year forecast that shows growing upside through 2050. The forecast implies meaningful upside over the coming years while recognizing the inherent uncertainty in any price projection.
The 30-day technical picture shows bullish momentum with RSI at 60 and trend indicators positioned to support upside. Key levels include a SMA50 of $3.20 and a SMA200 of $2.59, with immediate support at $2.78 and resistance at $4.15, framing a 30-day price range of $2.66 to $5.01.
Overall, the forecast points to substantial upside over the long term, with rising averages and high potential returns, alongside the usual uncertainties inherent in biotech equities and trial outcomes.
A major floor 42.8% below — a decisive break under it would weaken the trend.
The nearest floor, 27.4% below — buyers have tended to step in here.
The nearest ceiling, 8.4% above — a clean break opens room to run.
A major ceiling 29.4% above — clearing it would confirm fresh momentum.
Key CABA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CABA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.67 | Buy | $3.68 | Buy |
| MA 10 | $3.54 | Buy | $3.61 | Buy |
| MA 20 | $3.56 | Buy | $3.53 | Buy |
| MA 50 | $3.23 | Buy | $3.32 | Buy |
| MA 100 | $3.00 | Buy | $3.07 | Buy |
| MA 200 | $2.62 | Buy | $2.89 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 59.89 | Neutral |
| Stoch RSI (14) | 72.19 | Neutral |
| CCI (20) | 63.02 | Neutral |
| Williams %R (14) | -23.29 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | -1.29 | Sell |
| Bollinger %B (20,2) | 0.69 | Neutral |
| Stochastic %K (14) | 76.71 | Neutral |
| TRIX (15) | 0.51 | Buy |
| Awesome (5,34) | 0.26 | Buy |
| Ultimate (7,14,28) | 73.20 | Sell |
| Momentum (10) | 0.20 | Buy |
| Aroon Osc (25) | 16.00 | Buy |
| Hull MA (9) | 3.82 | Buy |
| ADX (14) | 14.27 | Neutral |
| ATR (14) | 0.14 | Info |
The 30-day technical picture is bullish. RSI14 is 60, and the stock trades with a near-term bullish tilt, supported by a SMA50 of $3.20 and a SMA200 of $2.59. Immediate support is at $2.78 and resistance at $4.15, framing a 30-day range from $2.66 to $5.01.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.04 | $3.83 | $5.32 | 0% | Neutral | |
| $3.83 | $5.16 | $7.50 | +35% | Bullish | |
| $4.56 | $6.45 | $9.91 | +69% | Bullish | |
| $5.50 | $8.13 | $13.02 | +112% | Bullish | |
| $5.20 | $7.98 | $13.23 | +108% | Bullish | |
| $5.20 | $8.27 | $14.14 | +116% | Bullish | |
| $5.90 | $9.70 | $17.05 | +153% | Bullish | |
| $5.23 | $8.88 | $15.99 | +132% | Bullish | |
| $6.29 | $11.00 | $20.27 | +187% | Bullish | |
| $8.52 | $15.37 | $28.92 | +301% | Bullish | |
| $8.87 | $18.44 | $37.79 | +381% | Bullish | |
| $21.41 | $47.57 | $109.41 | +11.4x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $2.04 | $3.83 | $4.57 | +0.00% |
| June 2026 | $3.27 | $3.89 | $4.79 | +1.68% |
| July 2026 | $3.17 | $3.83 | $4.82 | -1.62% |
| August 2026 | $3.28 | $4.01 | $5.13 | +4.71% |
| September 2026 | $3.30 | $4.07 | $5.28 | +1.48% |
| October 2026 | $3.07 | $3.82 | $5.02 | -6.11% |
| November 2026 | $3.00 | $3.76 | $4.99 | -1.60% |
| December 2026 | $3.14 | $3.97 | $5.32 | +5.49% |
Click any year to see its month-by-month CABA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Cabaletta Bio, Inc.'s 2026 outlook centres on $3.83, within a $2.04 to $5.32 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, CABA could reach as high as $7.50, with a base case around $5.16 and support toward $3.83 — roughly +35% from $3.83. Buyers look set to stay in control over this stretch.
Expect CABA to range from $4.56 to $9.91 through 2028. The $6.45 average target implies a +69% move from current prices. That is up +25% on the projected 2027 average. Momentum favours further upside here.
The CABA price prediction for 2029 points to an average of $8.13 (low $5.50, high $13.02) — a potential gain of +112% on today's $3.83. Buyers look set to stay in control over this stretch.
In 2030, CABA is projected to trade between $5.20 and $13.23, averaging $7.98 — a potential gain of +108% from today's $3.83. That is -2% versus the projected 2029 average. Momentum favours further upside here.
Cabaletta Bio, Inc.'s 2031 outlook centres on $8.27, within a $5.20 to $14.14 range. That is up +4% on the projected 2030 average. That marks a +116% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, CABA could reach as high as $17.05, with a base case around $9.70 and support toward $5.90 — roughly +153% from $3.83. Momentum favours further upside here.
Expect CABA to range from $5.23 to $15.99 through 2033. The $8.88 average target implies a +132% move from current prices. That is -8% versus the projected 2032 average. Buyers look set to stay in control over this stretch.
The CABA price prediction for 2034 points to an average of $11.00 (low $6.29, high $20.27) — a potential gain of +187% on today's $3.83. Momentum favours further upside here.
In 2035, CABA is projected to trade between $8.52 and $28.92, averaging $15.37 — a potential gain of +301% from today's $3.83. That is up +40% on the projected 2034 average. Buyers look set to stay in control over this stretch.
Cabaletta Bio, Inc.'s 2040 outlook centres on $18.44, within a $8.87 to $37.79 range. That is up +20% on the projected 2035 average. That marks a +381% change versus current levels. Momentum favours further upside here.
By 2050, CABA could reach as high as $109.41, with a base case around $47.57 and support toward $21.41 — roughly +11.4x from $3.83. Buyers look set to stay in control over this stretch.
Investing $1,000 in CABA today (≈ 261.096606 CABA) could be worth
$12,420.44
+$11,420.44 (+1142%) by 2050 · US Dollar
Based on the average projected CABA price of $47.57 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CABAwould be worth at today's price.
$1,000 invested in CABA on May 27, 2025 (≈ 574.712641 CABA) would be worth
$2,201.15
+$1,201.15 (+120.1%) today · 2.20× · US Dollar
Based on a CABA entry price of $1.74 vs. today's $3.83.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3.44 | $1,113.37 | +11.3% |
| 1 month ago | $2.91 | $1,316.15 | +31.6% |
| 3 months ago | $3.48 | $1,100.57 | +10.1% |
| 6 months ago | $2.57 | $1,490.27 | +49.0% |
| 1 year ago | $1.74 | $2,201.15 | +120.1% |
| All time (5.0y) ago | $11 | $348.18 | -65.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CABA forecast.
Our base-case forecast reaches $7.70 around 2029.
Implied market cap at $7.70: $1.26B
The multi-year forecast shows a path of sustained upside. In 2026 the avg price is $3.65 with a min of $2.04 and a max of $5.03, and an ROI of 0%. In 2027 the avg is $4.70 with a max of $6.90 and an ROI of 28.6%, followed by 2028 with an avg of $5.88 (ROI 61.1%), and 2029 with an avg of $7.38 (ROI 102.2%).
By 2030 the avg is $7.09 (ROI 94.3%), 2031 $7.33 (ROI 100.8%), 2032 $8.49 (ROI 132.5%), 2033 $7.45 (ROI 104%), 2034 $9.26 (ROI 153.7%), and 2035 $13.10 (ROI 258.8%). The forecast continues into 2040 with an avg of $15.19 (ROI 316.1%) and into 2050 with an avg of $38.48 (ROI 954.4%). The sentiment across these years is bullish.
Drivers of long-term potential include the company’s lead candidate in Phase 1/2 trials for multiple autoimmune diseases and collaborations with research institutions and contract partners, though these figures are estimates and not guarantees of future results.
Tap a question to reveal the answer.
The 2030 forecast shows an avg price of $7.09, with a min of $4.54 and a max of $11.94, and a projected ROI of 94.3% with bullish sentiment.
Forecasts show bullish sentiment in 2027-2050 with rising avg prices and positive ROI (e.g., 2027 avg $4.70, ROI 28.6%; 2050 avg $38.48, ROI 954.4%). In 2026 the avg is $3.65 with neutral sentiment and ROI 0%. These are estimates, not guarantees.
Yes, the forecast max by 2035 is $25.10 and by 2040 is $31.79, with a path that could reach or exceed $20, but these are speculative estimates and not guaranteed.
Current price is $3.65 per share and the market cap is $595.15M.
Bullish sentiment with RSI 14 at 60. SMA50 is $3.20 and SMA200 is $2.59. Support is at $2.78 and resistance at $4.15, with a 30-day price range of $2.66 to $5.01.
Cabaletta Bio, Inc. Community Discussion
0Share your Cabaletta Bio, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.